Valuation: Apogee Therapeutics, Inc.

Market Cap 10.16B 8.7B 8.15B 7.46B 13.99B 972B 14.18B 96.23B 37.53B 488B 38.16B 37.33B 1,616B P/E 2026 *
-28.9x
P/E 2027 * -23.5x
Enterprise Value 9.56B 8.19B 7.66B 7.01B 13.16B 915B 13.34B 90.52B 35.3B 459B 35.89B 35.11B 1,520B EV / Sales 2026 *
-
EV / Sales 2027 * 826x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 week+0.15%
Current month+0.49%
1 month+0.36%
3 months+66.03%
6 months+92.75%
Current year+78.52%
1 week 134.54
Extreme 134.54
134.88
1 month 134.03
Extreme 134.03
134.88
Current year 60.35
Extreme 60.35
134.88
1 year 35.39
Extreme 35.39
134.88
3 years 14.19
Extreme 14.19
134.88
5 years 14.19
Extreme 14.19
134.88
10 years 14.19
Extreme 14.19
134.88
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
7/8/26
Fairmount Funds Management LLC
Fiscal yearCompany 84,416 0.1507%
7/8/26 Other

Director

0 0%
7/8/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.15%+252.10%+448.88% 10.16B
-1.08%+3.46%+2.30%+22.72% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
-0.14%+4.00%+9.08%+30.05% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.18%+4.01%+101.91%+158.63% 28.66B
Weighted average by Cap. +0.08%+4.55%+105.03%+152.84%

Financials

2026 *2027 *
Net sales - 11.54M 9.88M 9.25M 8.47M 15.89M 1.1B 16.1M 109M 42.61M 555M 43.33M 42.38M 1.83B
Net income -341M -292M -273M -250M -470M -32.64B -476M -3.23B -1.26B -16.4B -1.28B -1.25B -54.23B -422M -362M -338M -310M -581M -40.41B -589M -4B -1.56B -20.3B -1.59B -1.55B -67.14B
Net Debt -604M -517M -484M -443M -831M -57.75B -842M -5.72B -2.23B -29.01B -2.27B -2.22B -95.95B -630M -540M -505M -462M -868M -60.28B -879M -5.97B -2.33B -30.28B -2.37B -2.31B -100B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
21/08/26 USD 134.75 0.00% 948,283
20/08/26 USD 134.75 +0.03% 1,162,505
19/08/26 USD 134.71 +0.10% 1,417,489
18/08/26 USD 134.57 -0.01% 992,187
17/08/26 USD 134.59 +0.03% 1,949,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
134.75USD
Average target price
134.85USD
Spread / Average Target
+0.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock